CGCP yields 5.16% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, CGCP + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGCP + PFE for your $10,000?
The fund's investment objective is to provide current income and seek maximum total return, consistent with preservation of capital.Distinguishing Characteristics Government debt and agency bonds, corporate bonds, mortgage- and asset-backed securities, emerging markets debt, non-U.S., municipals and high-yield.The bond maturities that the fund targets will vary depending on the current strategy being implemented.The fund may invest no more than 35% of its assets in securities rated below investment grade (BB+/Ba1 and below, or unrated, but determined by the fund's investment adviser to be of equivalent quality) at the time of purchase, including high-yield corporate bonds or those issued by developing country governments and companies. The fund may invest up to 10% of its assets in equity securities and certain securities with a combination of debt and equity characteristics. The fund may invest up to 35% of its assets in securities denominated in currencies other than the U.S. dollar. The fund may invest up to 35% of its assets in securities of emerging market issuers.
Full CGCP Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.